{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:48:26Z","timestamp":1777333706354,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82171196"],"award-info":[{"award-number":["82171196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Key Research and Development Program of Henan Province","award":["241111313500"],"award-info":[{"award-number":["241111313500"]}]},{"name":"the Medical Science and Technology Research Project of Henan Province","award":["SBGJ202402012"],"award-info":[{"award-number":["SBGJ202402012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-026-02016-5","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:23:56Z","timestamp":1773883436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical, neuroimaging, and biomarker profiling of four Alzheimer\u2019s disease pedigrees caused by pathogenic APP variants"],"prefix":"10.1186","volume":"18","author":[{"given":"Jie-Wen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Xin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Di","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"2016_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ncl.2017.01.005","volume":"35","author":"MF Mendez","year":"2017","unstructured":"Mendez MF. Early-Onset Alzheimer Disease. Neurol Clin. 2017;35:263\u201381. https:\/\/doi.org\/10.1016\/j.ncl.2017.01.005.","journal-title":"Neurol Clin"},{"key":"2016_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2011","unstructured":"Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, et al. Autosomal-dominant Alzheimer\u2019s disease: a review and proposal for the prevention of Alzheimer\u2019s disease. Alzheimers Res Ther. 2011;3:1. https:\/\/doi.org\/10.1186\/alzrt59.","journal-title":"Alzheimers Res Ther"},{"key":"2016_CR3","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S1474-4422(16)30193-4","volume":"15","author":"NS Ryan","year":"2016","unstructured":"Ryan NS, Nicholas JM, Weston PSJ, Liang Y, Lashley T, Guerreiro R, et al. Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer\u2019s disease: a case series. Lancet Neurol. 2016;15:1326\u201335. https:\/\/doi.org\/10.1016\/S1474-4422(16)30193-4.","journal-title":"Lancet Neurol"},{"key":"2016_CR4","doi-asserted-by":"publisher","first-page":"e31039","DOI":"10.1371\/journal.pone.0031039","volume":"7","author":"C Cruchaga","year":"2012","unstructured":"Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FLM, Mitra RD, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer\u2019s disease families. PLoS ONE. 2012;7:e31039. https:\/\/doi.org\/10.1371\/journal.pone.0031039.","journal-title":"PLoS ONE"},{"key":"2016_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136. https:\/\/doi.org\/10.1126\/science.1072994.","journal-title":"Science"},{"key":"2016_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. Cell. 2019;179:312\u201339. https:\/\/doi.org\/10.1016\/j.cell.2019.09.001.","journal-title":"Cell"},{"key":"2016_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"2016_CR8","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18:2669\u201386. https:\/\/doi.org\/10.1002\/alz.12756.","journal-title":"Alzheimers Dement"},{"key":"2016_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16:661\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(17)30159-X.","journal-title":"Lancet Neurol"},{"key":"2016_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2021.4654","volume":"79","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Smith R, Cullen NC, Strandberg O, Vogel JW, Binette AP, et al. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurol. 2022;79:149\u201358. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4654.","journal-title":"JAMA Neurol"},{"key":"2016_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2022;79:13\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4161.","journal-title":"JAMA Neurol"},{"key":"2016_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med. 2020;26:398\u2013407. https:\/\/doi.org\/10.1038\/s41591-020-0781-z.","journal-title":"Nat Med"},{"key":"2016_CR13","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146:1592\u2013601. https:\/\/doi.org\/10.1093\/brain\/awac333.","journal-title":"Brain"},{"key":"2016_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141:709\u201324. https:\/\/doi.org\/10.1007\/s00401-021-02275-6.","journal-title":"Acta Neuropathol"},{"key":"2016_CR15","doi-asserted-by":"publisher","first-page":"6635","DOI":"10.1038\/s41467-022-34129-4","volume":"13","author":"A Pichet Binette","year":"2022","unstructured":"Pichet Binette A, Franzmeier N, Spotorno N, Ewers M, Brendel M, Biel D, et al. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer\u2019s disease. Nat Commun. 2022;13:6635. https:\/\/doi.org\/10.1038\/s41467-022-34129-4.","journal-title":"Nat Commun"},{"key":"2016_CR16","doi-asserted-by":"publisher","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease. Sci Adv. 2020;6:eaaz2387. https:\/\/doi.org\/10.1126\/sciadv.aaz2387.","journal-title":"Sci Adv"},{"key":"2016_CR17","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349:704\u20136. https:\/\/doi.org\/10.1038\/349704a0.","journal-title":"Nature"},{"key":"2016_CR18","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253\u201360. https:\/\/doi.org\/10.1212\/WNL.0000000000000596.","journal-title":"Neurology"},{"key":"2016_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-023-02318-3","volume":"29","author":"F Lopera","year":"2023","unstructured":"Lopera F, Marino C, Chandrahas AS, O\u2019Hare M, Villalba-Moreno ND, Aguillon D, et al. Resilience to autosomal dominant Alzheimer\u2019s disease in a Reelin-COLBOS heterozygous man. Nat Med. 2023;29:1243\u201352. https:\/\/doi.org\/10.1038\/s41591-023-02318-3.","journal-title":"Nat Med"},{"key":"2016_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020;77:829\u201339. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0528.","journal-title":"JAMA Neurol"},{"key":"2016_CR21","doi-asserted-by":"publisher","unstructured":"Jiao B, Tang B, Liu X, Xu J, Wang Y, Zhou L, et al. Mutational analysis in early-onset familial Alzheimer\u2019s disease in Mainland China. Neurobiol Aging. 2014;35:1957.e1-6. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2014.02.014.\u00a0","DOI":"10.1016\/j.neurobiolaging.2014.02.014"},{"key":"2016_CR22","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurol. 2021;78:1471\u201383. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3671.","journal-title":"JAMA Neurol"},{"key":"2016_CR23","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K et al. Alzheimer\u2019s Disease Neuroimaging Initiative,. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27:1034\u201342. https:\/\/doi.org\/10.1038\/s41591-021-01348-z","DOI":"10.1038\/s41591-021-01348-z"},{"key":"2016_CR24","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen CE, et al. Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain. 2021;144:3505\u201316. https:\/\/doi.org\/10.1093\/brain\/awab223.","journal-title":"Brain"},{"key":"2016_CR25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577\u201389. https:\/\/doi.org\/10.1038\/s41582-018-0058-z.","journal-title":"Nat Rev Neurol"},{"key":"2016_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jalz.2018.01.012","volume":"14","author":"CL Sutphen","year":"2018","unstructured":"Sutphen CL, McCue L, Herries EM, Xiong C, Ladenson JH, Holtzman DM, et al. Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:869\u201379. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.012.","journal-title":"Alzheimers Dement"},{"key":"2016_CR27","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1093\/brain\/awab166","volume":"144","author":"A O\u2019Connor","year":"2021","unstructured":"O\u2019Connor A, Pannee J, Poole T, Arber C, Portelius E, Swift IJ, et al. Plasma amyloid-\u03b2 ratios in autosomal dominant Alzheimer\u2019s disease: the influence of genotype. Brain. 2021;144:2964\u201370. https:\/\/doi.org\/10.1093\/brain\/awab166.","journal-title":"Brain"},{"key":"2016_CR28","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M, et al. Association of Apolipoprotein E \u03b54 With Medial Temporal Tau Independent of Amyloid-\u03b2. JAMA Neurol. 2020;77:470\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4421.","journal-title":"JAMA Neurol"},{"key":"2016_CR29","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12131","volume":"16","author":"M Mil\u00e0-Alom\u00e0","year":"2020","unstructured":"Mil\u00e0-Alom\u00e0 M, Salvad\u00f3 G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer\u2019s continuum. Alzheimers Dement. 2020;16:1358\u201371. https:\/\/doi.org\/10.1002\/alz.12131.","journal-title":"Alzheimers Dement"},{"key":"2016_CR30","doi-asserted-by":"publisher","first-page":"e1295","DOI":"10.1212\/WNL.0000000000006277","volume":"91","author":"E McDade","year":"2018","unstructured":"McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018;91:e1295\u2013306. https:\/\/doi.org\/10.1212\/WNL.0000000000006277.","journal-title":"Neurology"},{"key":"2016_CR31","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awz019","volume":"142","author":"BA Gordon","year":"2019","unstructured":"Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, et al. Tau PET in autosomal dominant Alzheimer\u2019s disease: relationship with cognition, dementia and other biomarkers. Brain. 2019;142:1063\u201376. https:\/\/doi.org\/10.1093\/brain\/awz019.","journal-title":"Brain"},{"key":"2016_CR32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1001\/jamaneurol.2020.0989","volume":"77","author":"A Leuzy","year":"2020","unstructured":"Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurol. 2020;77:955\u201365. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0989.","journal-title":"JAMA Neurol"},{"key":"2016_CR33","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL, et al. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 2021;78:149\u201356. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4201.","journal-title":"JAMA Neurol"},{"key":"2016_CR34","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28:2381\u20137. https:\/\/doi.org\/10.1038\/s41591-022-02049-x.","journal-title":"Nat Med"},{"key":"2016_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"2016_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, et al. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14:191. https:\/\/doi.org\/10.1186\/s13195-022-01124-2.","journal-title":"Alzheimers Res Ther"},{"key":"2016_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8.","journal-title":"Alzheimers Res Ther"},{"key":"2016_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","volume":"13","author":"RJ Bateman","year":"2017","unstructured":"Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, et al. The DIAN-TU Next Generation Alzheimer\u2019s prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 2017;13:8\u201319. https:\/\/doi.org\/10.1016\/j.jalz.2016.07.005.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-026-02016-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-026-02016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:23:06Z","timestamp":1777332186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-026-02016-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2016"],"URL":"https:\/\/doi.org\/10.1186\/s13195-026-02016-5","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Henan Provincial People\u2019s Hospital (approval no. 202076). Written informed consent was obtained from all participants or their legally authorized representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}